PURPOSE: Immunodeficient mice serve as critical hosts for transplantation of xenogeneic cells for in vivo analysis of various biological processes. Because investigators typically select one or two immunodeficient mouse strains as recipients, no comprehensive study has been published documenting differences in human tumor engraftment. Taking advantage of the increased metastatic potential of RhoC-expressing human (A375) melanoma cells, we evaluate four immunodeficient mouse strains: severe combined immunodeficiency (scid), nonobese diabetic (NOD)-scid, NOD-scid beta2m(null), and NOD-scid IL2Rgamma(null) as xenograft tumor recipients. EXPERIMENTAL DESIGN: Bioluminescence, magnetic resonance imaging, and histopathology were used to monitor serial tumor growth. Natural killer (NK) cell function was examined in each mouse strain using standard (51)Chromium release assays. RESULTS: Melanoma metastases growth is delayed and variable in scid and NOD-scid mice. In contrast, NOD-scid beta2m(null) and NOD-scid IL2Rgamma(null) mice show rapid tumor engraftment, although tumor growth is variable in NOD-scid beta2m(null) mice. NK cells were detected in all strains except NOD-scid IL2Rgamma(null), and in vitro activated scid, NOD-scid, and NOD-scid beta2m(null) NK cells kill human melanoma lines and primary melanoma cells. Expression of human NKG2D ligands MHC class I chain-related A and B molecules renders melanoma susceptible to murine NK cell-mediated cytotoxicity and killing is inhibited by antibody blockade of murine NKG2D. CONCLUSIONS: Murine NKG2D recognition of MICA/B is an important receptor-ligand interaction used by NK cells in immunodeficient strains to limit engraftment of human tumors. The absolute NK deficiency in NOD-scid IL2Rgamma(null) animals makes this strain an excellent recipient of melanoma and potentially other human malignancies.
PURPOSE:Immunodeficientmice serve as critical hosts for transplantation of xenogeneic cells for in vivo analysis of various biological processes. Because investigators typically select one or two immunodeficientmouse strains as recipients, no comprehensive study has been published documenting differences in humantumor engraftment. Taking advantage of the increased metastatic potential of RhoC-expressing human (A375) melanoma cells, we evaluate four immunodeficientmouse strains: severe combined immunodeficiency (scid), nonobese diabetic (NOD)-scid, NOD-scidbeta2m(null), and NOD-scid IL2Rgamma(null) as xenograft tumor recipients. EXPERIMENTAL DESIGN: Bioluminescence, magnetic resonance imaging, and histopathology were used to monitor serial tumor growth. Natural killer (NK) cell function was examined in each mouse strain using standard (51)Chromium release assays. RESULTS:Melanoma metastases growth is delayed and variable in scid and NOD-scidmice. In contrast, NOD-scidbeta2m(null) and NOD-scid IL2Rgamma(null) mice show rapid tumor engraftment, although tumor growth is variable in NOD-scidbeta2m(null) mice. NK cells were detected in all strains except NOD-scid IL2Rgamma(null), and in vitro activated scid, NOD-scid, and NOD-scidbeta2m(null) NK cells kill humanmelanoma lines and primary melanoma cells. Expression of humanNKG2D ligands MHC class I chain-related A and B molecules renders melanoma susceptible to murine NK cell-mediated cytotoxicity and killing is inhibited by antibody blockade of murineNKG2D. CONCLUSIONS:MurineNKG2D recognition of MICA/B is an important receptor-ligand interaction used by NK cells in immunodeficient strains to limit engraftment of humantumors. The absolute NK deficiency in NOD-scid IL2Rgamma(null) animals makes this strain an excellent recipient of melanoma and potentially other humanmalignancies.
Authors: Kouetsu Ogasawara; Jessica A Hamerman; Honor Hsin; Shunsuke Chikuma; Helene Bour-Jordan; Taian Chen; Thomas Pertel; Claude Carnaud; Jeffrey A Bluestone; Lewis L Lanier Journal: Immunity Date: 2003-01 Impact factor: 31.745
Authors: Emily L Ho; Leonidas N Carayannopoulos; Jennifer Poursine-Laurent; Jeremy Kinder; Beatrice Plougastel; Hamish R C Smith; Wayne M Yokoyama Journal: J Immunol Date: 2002-10-01 Impact factor: 5.422
Authors: D Pende; C Cantoni; P Rivera; M Vitale; R Castriconi; S Marcenaro; M Nanni; R Biassoni; C Bottino; A Moretta; L Moretta Journal: Eur J Immunol Date: 2001-04 Impact factor: 5.532
Authors: LauraL Carter; Lynette A Fouser; Jason Jussif; Lori Fitz; Bija Deng; Clive R Wood; Mary Collins; Tasuku Honjo; Gordon J Freeman; Beatriz M Carreno Journal: Eur J Immunol Date: 2002-03 Impact factor: 5.532
Authors: Leonard D Shultz; Scott J Banuelos; Jean Leif; Michael C Appel; Melody Cunningham; Karen Ballen; Lisa Burzenski; Dale L Greiner Journal: Exp Hematol Date: 2003-06 Impact factor: 3.084
Authors: Vanessa K Tidwell; Joel R Garbow; Alexander S Krupnick; John A Engelbach; Arye Nehorai Journal: Magn Reson Med Date: 2011-09-27 Impact factor: 4.668
Authors: C Patrick Reynolds; Min H Kang; Stephen T Keir; Richard Gorlick; E Anders Kolb; Richard Lock; John M Maris; Hernan Carol; Christopher L Morton; Catherine A Billups; Malcolm A Smith; Peter J Houghton Journal: Pediatr Blood Cancer Date: 2011-02-25 Impact factor: 3.167
Authors: Aaron Y Chang; Tao Dao; Ron S Gejman; Casey A Jarvis; Andrew Scott; Leonid Dubrovsky; Melissa D Mathias; Tatyana Korontsvit; Victoriya Zakhaleva; Michael Curcio; Ronald C Hendrickson; Cheng Liu; David A Scheinberg Journal: J Clin Invest Date: 2017-06-19 Impact factor: 14.808
Authors: Ruben G Nava; Wenjun Li; Andrew E Gelman; Alexander S Krupnick; Mark J Miller; Daniel Kreisel Journal: Semin Immunopathol Date: 2010-06-30 Impact factor: 9.623
Authors: Judit Dobos; Anita Mohos; József Tóvári; Erzsébet Rásó; Tamás Lőrincz; Gergely Zádori; József Tímár; Andrea Ladányi Journal: Clin Exp Metastasis Date: 2012-12-01 Impact factor: 5.150